Eisai to Hold Clinical Trials for Diabetes Drug
Posted on: Friday, 30 September 2005, 15:00 CDT
By From staff, news service reports
Eisai Co., Japan's fourth-largest pharmaceutical maker, said Thursday that it will conduct clinical trials for a drug that treats a complication of diabetes at its medical research facilities in Ridgefield Park.
The drug, originated by Dainippon Pharmaceutical Co., is called AS-3201 and is in the last of three stages of clinical tests in the U.S. and Canada, the two companies said in a statement filed at the Tokyo Stock Exchange.
"If the trial proves successful, we will submit a new drug application in the United States, and then Eisai Inc. will be able to continue with the manufacturing and marketing of the product," spokeswoman Julia Lamm said. Eisai, the maker of the Aricept Alzheimer's treatment, has its U.S. corporate headquarters in Teaneck.
The company has a total of 450 employees at the two locations.
In Japan, Osaka-based Dainippon is conducting second-phase clinical trials of the drug with Kyorin Pharmaceutical Co., a Tokyo- based maker of prescription drugs and medical supplies.
The two companies say an estimated 3.6 million people in the U.S. and 1.7 million in Japan are affected by diabetic neuropathy, a complication of diabetes that affects the nervous system.
Dainippon Pharma will retain Japan rights to the drug, the statement said.
Separately, Eisai Inc. said Thursday it has entered an agreement with Pfizer Inc. for exclusive U.S. rights to promote the clot- preventing drug Fragmin.
Under the terms of the agreement, Eisai will assume responsibility for Fragmin's post-marketing studies and product distribution, as well as book all U.S. sales.
Staff Writer Kevin G. DeMarrais contributed to this article, which contains material from Bloomberg News.
Source: Record, The; Bergen County, N.J.
Related Articles
- Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
- RegeneRx Names Drug Products Under Clinical Development
- Current Pharmaceutical Pipelines Are Testimony to the Intensity of Breast Cancer Drug Development With At Least 50 Investigational Drugs/Drug Combinations in Clinical Development
- MultiCell Signs License Agreement With Eisai Japan to Use Fa2N-4 Cell Line for Drug Discovery/ADMETOX Applications
- Research and Markets: The Evolving Strategies of Generics Company Teva and the Growing Acceptance of Generic Drugs in Japan, Read More Inside 'State of the Pharmaceutical Industry, 2007'
- BioLineRx Raises an Additional $9 Million and Advances Pipeline of Drug Candidates Toward Clinical Trials
- Kinex Pharmaceuticals Selects Lead Drug Candidate for Clinical Development in Oncology
- Geron Announces Publication Characterizing GRN163L, Its Telomerase Inhibitor Drug Currently in Clinical Development for Cancer
- HepaLife Announces Addition of Toxicology Scientist, to Develop Testing Platform for Liver Toxicity -- the Leading Cause of Drug Withdrawals From Clinical Use
- Obesity Boosts Drug Spending; Mayo Clinic Study Says Extra Weight Increases Prescription Tab for Men
 |
 |
User Comments (0)
RSS Feeds